Jian Zhang1, Meong Cheol Shin, Victor C Yang. 1. Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnosis School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Abstract
PURPOSE: A novel PEGylated and heparinized magnetic iron oxide nano-platform (DNPH) was synthesized for simultaneous magnetic resonance imaging (MRI) and tumor targeting. METHODS: Starch-coated magnetic iron oxide nanoparticles ("D") were crosslinked, aminated (DN) and then simultaneously PEGylated and heparinized with different feed ratios of PEG and heparin (DNPH1-4). DNPH products were characterized by Fourier transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM) and superconducting quantum interference device (SQUID). The magentic targeting of DNPH3, with appropriate amounts of conjugated PEG and heparin, in a mouse 9L-glioma subcutaneous tumor model was confirmed by magnetic resonance imaging (MRI)/electron spin resonance (ESR). RESULTS: DNPH3 showed long circulating properties in vivo (half-life >8 h, more than 60-fold longer than that of parent D) and low reticuloendothelial system (RES) recognition in liver and spleen. Protamine, a model cationic protein, was efficiently loaded onto DNPH3 with a maximum loading content of 26.4 μg/mg Fe. Magnetic capture of DNPH3 in tumor site with optimized conditions (I.D. of 12 mg/kg, targeting time of 45 min) was up to 29.42 μg Fe/g tissue (12.26% I.D./g tissue). CONCLUSION: DNPH3 showed the potential to be used as a platform for cationic proteins for simultaneous tumor targeting and imaging.
PURPOSE: A novel PEGylated and heparinized magnetic iron oxide nano-platform (DNPH) was synthesized for simultaneous magnetic resonance imaging (MRI) and tumor targeting. METHODS:Starch-coated magnetic iron oxide nanoparticles ("D") were crosslinked, aminated (DN) and then simultaneously PEGylated and heparinized with different feed ratios of PEG and heparin (DNPH1-4). DNPH products were characterized by Fourier transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM) and superconducting quantum interference device (SQUID). The magentic targeting of DNPH3, with appropriate amounts of conjugated PEG and heparin, in a mouse9L-glioma subcutaneous tumor model was confirmed by magnetic resonance imaging (MRI)/electron spin resonance (ESR). RESULTS:DNPH3 showed long circulating properties in vivo (half-life >8 h, more than 60-fold longer than that of parent D) and low reticuloendothelial system (RES) recognition in liver and spleen. Protamine, a model cationic protein, was efficiently loaded onto DNPH3 with a maximum loading content of 26.4 μg/mg Fe. Magnetic capture of DNPH3 in tumor site with optimized conditions (I.D. of 12 mg/kg, targeting time of 45 min) was up to 29.42 μg Fe/g tissue (12.26% I.D./g tissue). CONCLUSION:DNPH3 showed the potential to be used as a platform for cationic proteins for simultaneous tumor targeting and imaging.
Authors: R M Sawant; J P Hurley; S Salmaso; A Kale; E Tolcheva; T S Levchenko; V P Torchilin Journal: Bioconjug Chem Date: 2006 Jul-Aug Impact factor: 4.774
Authors: Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall Journal: Nat Cell Biol Date: 2007-05-07 Impact factor: 28.824
Authors: Young Min Kwon; Yongtao Li; Sarita Naik; Jun Feng Liang; Yongzhuo Huang; Yoon Jeong Park; Victor C Yang Journal: Expert Opin Drug Deliv Date: 2008-11 Impact factor: 6.648
Authors: Bo Zhu; Thomas Witzel; Shan Jiang; Susie Y Huang; Bruce R Rosen; Lawrence L Wald Journal: Magn Reson Med Date: 2014-12-23 Impact factor: 4.668
Authors: Karina A Crespo; José L Baronetti; Melisa A Quinteros; Paulina L Páez; María G Paraje Journal: Pharm Res Date: 2016-12-19 Impact factor: 4.200
Authors: Zhizhi Sun; Matthew Worden; Yaroslav Wroczynskyj; Vinith Yathindranath; Johan van Lierop; Torsten Hegmann; Donald W Miller Journal: Int J Nanomedicine Date: 2014-06-20